RESUMEN
RESUMEN Objetivos. Investigar los efectos del D-002, mezcla de seis alcoholes alifáticos primarios de alto peso molecular, obtenida de la cera de abejas (Apis mellifera), sobre la colitis ulcerativa (CU) inflamatoria severa inducida por sulfato de dextrano (DSS) y etanol en ratas (Ratus ratus). Materiales y métodos. Las ratas se distribuyeron aleatoriamente en seis grupos: un control cero al que no se provocó daño, y cinco a los que se les indujo la CU: un control negativo (vehículo), tres tratados con D-002 (25, 100 y 400 mg/kg) y un control positivo con sulfazalacina (200 mg/kg) (sustancia de referencia). Se cuantificaron las manifestaciones clínicas (variación del peso corporal, presencia de diarrea y de sangrado rectal), el puntaje de daño macroscópico e histológico, y la actividad de mieoloperoxidasa (MPO). Resultados. El tratamiento oral con D-002 (25, 100 y 400 mg/kg) previno significativamente la disminución del peso corporal. La dosis de 400 mg/kg redujo la presencia de diarreas y sangrado rectal, aunque su comparación con el control negativo solo alcanzó significación estadística sobre las diarreas. El D-002 (25, 100 y 400 mg/kg) redujo significativamente el puntaje de las lesiones macroscópicas (40,0; 43,3 y 47,2% de inhibición, respectivamente), el puntaje de daño histológico (31,5; 53,7 y 67,1% de inhibición, respectivamente) y la actividad de MPO (73,2; 83,6 y 85,0% de inhibición, respectivamente), comparado con el grupo control negativo. La sulfazalacina redujo significativamente todas las variables estudiadas. Conclusiones. El D-002 (25, 100 y 400 mg/kg) protegió significativamente la mucosa colónica en ratas con CU inflamatoria severa inducida por DSS y etanol.
ABSTRACT Objectives. To investigate the effects of D-002, a mixture of 6 high molecular weight primary aliphatic alcohols, obtained from beeswax (Apis mellifera), on severe inflammatory ulcerative colitis (UC) induced by Dextran sulfate (DSS) and ethanol in rats (Ratus ratus). Materials and methods. Rats were randomly distributed in six groups: a zero control to which no damage was caused, and five to which the UC was induced: a negative control (vehicle), three treated with D-002 (25, 100 and 400 mg/kg) and a positive control with sulfasalazine (200 mg/kg) (reference substance). Clinical manifestations (body weight variation, diarrhea and rectal bleeding), macroscopic and histological damage score, and myeloperoxidase (MPO) activity were quantified. Results. The oral treatment with D-002 (25, 100 and 400 mg/ kg) significantly prevented the decrease in body weight. The dose of 400 mg/kg reduced the presence of diarrhea and rectal bleeding, although its comparison with the negative control only reached statistical significance on diarrhea. D-002 (25, 100 and 400 mg/kg) significantly reduced the score of macroscopic lesions (40.0; 43.3 and 47.2% inhibition, respectively), the histological damage score (31.5; 53.7 and 67.1% inhibition, respectively) and the activity of MPO (73.2; 83.6 and 85.0% inhibition, respectively), compared to the negative control group. Sulfasalazine significantly reduced all variables studied. Conclusions. D-002 (25, 100 and 400 mg/kg) significantly protected the colonic mucosa in rats with severe inflammatory UC induced by DSS and ethanol.
Asunto(s)
Animales , Masculino , Ratas , Colitis Ulcerosa/tratamiento farmacológico , Alcoholes Grasos/uso terapéutico , Colitis Ulcerosa/inducido químicamente , Distribución Aleatoria , Sulfato de Dextran/administración & dosificación , Ratas Sprague-Dawley , Etanol/administración & dosificaciónAsunto(s)
Animales , Masculino , Ratas , FN-kappa B/metabolismo , Poli(ADP-Ribosa) Polimerasas/metabolismo , Surfactantes Pulmonares/farmacología , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , /farmacología , /uso terapéutico , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/citología , Citrulina/metabolismo , Combinación de Medicamentos , Activación Enzimática , Alcoholes Grasos/farmacología , Alcoholes Grasos/uso terapéutico , Concentración de Iones de Hidrógeno , Quinasa I-kappa B/metabolismo , Lipopolisacáridos , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Pulmón/patología , FN-kappa B/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/metabolismo , Nitritos/metabolismo , Células Epiteliales Alveolares/efectos de los fármacos , Células Epiteliales Alveolares/metabolismo , Poli(ADP-Ribosa) Polimerasas/antagonistas & inhibidores , Polietilenglicoles/farmacología , Polietilenglicoles/uso terapéutico , Surfactantes Pulmonares/uso terapéutico , Ratas Sprague-Dawley , Síndrome de Dificultad Respiratoria/inducido químicamente , Síndrome de Dificultad Respiratoria/metabolismo , PorcinosRESUMEN
No abstract available.
Asunto(s)
Femenino , Humanos , Masculino , Antiinfecciosos/uso terapéutico , Alcoholes Grasos/uso terapéutico , Osteoartritis/tratamiento farmacológicoRESUMEN
During the last three decades, a better understanding of viral replication and disease states caused by viral infections have led to the development of newer antiviral agents with enhanced activity and better tolerability. This review focuses on newer systemic and topical antiviral agents that are used in treatment of herpes viruses including herpes simplex type-1 (HSV-1) and type-2 (HSV-2), varicella-zoster virus (VZV) and cytomegalovirus CMV) as well as the human papilloma virus (HPV). Included in this article are the agents famciclovir, penciclovir, valganciclovir, imiquimod, docosanole and brivudin.
Asunto(s)
2-Aminopurina/análogos & derivados , Aciclovir/análogos & derivados , Aminoquinolinas/uso terapéutico , Antivirales/farmacología , Bromodesoxiuridina/análogos & derivados , Alcoholes Grasos/uso terapéutico , Ganciclovir/análogos & derivados , Humanos , Virosis/tratamiento farmacológicoAsunto(s)
Productos Biológicos , Combinación de Medicamentos , Alcoholes Grasos/uso terapéutico , Femenino , Humanos , Enfermedad de la Membrana Hialina/tratamiento farmacológico , Recién Nacido , Recien Nacido Prematuro , Masculino , Fosforilcolina , Polietilenglicoles/uso terapéutico , Surfactantes Pulmonares/uso terapéuticoRESUMEN
Policosanol is a mixture of higher aliphatic primary alcohols isolated from sugar cane wax, whose main component is octacosanol. An inhibitory effect of policosanol on platelet aggregation and cerebral ischemia in animal models has been reported. Thus, the objective of the present study was to evaluate the effect of policosanol on cerebral ischemia induced by unilateral carotid ligation and bilateral clamping and recirculation in Mongolian gerbils. Policosanol (200 mg/kg) administered immediately after unilateral carotid ligation and at 12- or 24-h intervals for 48 h significantly inhibited mortality and clinical symptoms when compared with controls, whereas lower doses (100 mg/kg) were not effective. Control animals showed swelling (tissue vacuolization) and necrosis of neurons in all areas of the brain studied (frontal cortex, hippocampus, striatum and olfactory tubercle), showing a similar injury profile. In the group treated with 200 mg/kg policosanol swelling and necrosis were significantly reduced when compared with the control group. In another experimental model, comparison between groups showed that the brain water content of control gerbils (N = 15) was significantly higher after 15 min of clamping and 4 h of recirculation than in sham-operated animals (N = 13), whereas policosanol (200 mg/kg) (N = 19) significantly reduced the edema compared with the control group, with a cerebral water content identical to that of the sham-operated animals. cAMP levels in the brain of control-ligated Mongolian gerbils (N = 8) were significantly lower than those of sham-operated animals (N = 10). The policosanol-treated group (N = 10) showed significantly higher cAMP levels (2.68 pmol/g of tissue) than the positive control (1.91 pmol/g of tissue) and similar to those of non-ligated gerbils (2.97 pmol/g of tissue). In conclusion, our results show an anti-ischemic effect of policosanol administered after induction of cerebral ischemia, in two different experimental models in Mongolian gerbils, suggesting a possible therapeutic effect in cerebral vascular disorders
Asunto(s)
Animales , Femenino , Isquemia Encefálica/terapia , AMP Cíclico/análisis , Alcoholes Grasos/uso terapéutico , Inhibidores de Agregación Plaquetaria/uso terapéutico , Isquemia Encefálica/patología , Constricción , Modelos Animales de Enfermedad , GerbillinaeAsunto(s)
Productos Biológicos , Combinación de Medicamentos , Alcoholes Grasos/uso terapéutico , Femenino , Humanos , Recién Nacido , Lípidos/uso terapéutico , Masculino , Fosfolípidos , Fosforilcolina , Polietilenglicoles/uso terapéutico , Surfactantes Pulmonares/uso terapéutico , Respiración Artificial , Síndrome de Dificultad Respiratoria del Recién Nacido/diagnóstico , Análisis de SupervivenciaRESUMEN
Panax ginseng roots have long been used as a medicinal herb in oriental countries. We have investigated anti-proliferative effects of lipid soluble Panax ginseng components on human renal cancer cell lines. Petroleum ether extract of Panax ginseng roots (GX-PE) or its partially purified preparation (7:3 GX) was added to cultures of three human renal cell carcinoma (RCC) cell lines, A498, Caki-1, and CURC II. Proliferation of RCC cells was estimated by a [3H]thymidine incorporation assay and cell cycle distribution was analyzed by flow cytometry. GX-PE, 7:3 GX, panaxydol and panaxynol inhibited proliferation of all three RCC cell lines in a dose dependent manner in vitro with an order of potency, 7:3 GX > panaxydol > panaxynol = GX-PE. Additive effect of interleukin 4 was also demonstrated, most prominently in Caki-1 which responded poorly to GX-PE alone. Analysis of cell cycle in CURC II and Caki-1 treated with GX-PE demonstrated increase in G1 phase population and corresponding decrease in S phase population. The present study demonstrated that proliferation of human RCC cell lines were inhibited by lipid soluble components of Panax ginseng roots by blocking cell cycle progression at G1 to S phase transition.